Cost‐effectiveness of recombinant factor <scp>VIII Fc</scp> versus emicizumab for prophylaxis in adults and adolescents with haemophilia <scp>A</scp> without inhibitors in the <scp>UK</scp>-Reference-Cited by-同舟云学术

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK

Published:2022-12-11 Issue:3 Volume:110 Page:262-270
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Kragh Nana¹,Tytula Anna²,Pochopien Michał³,Aballéa Samuel⁴,Toumi Mondher⁴,Hakimi Zalmai¹,Nazir Jameel⁵,Bystrická Linda⁶,Fatoye Francis⁷

Affiliation:

1. Global Health Economics and Outcomes Research Swedish Orphan Biovitrum AB (Sobi™) Stockholm Sweden

2. Health Economics and Outcomes Research Department Putnam PHMR Krakow Poland

3. Economic Modelling Assignity Krakow Poland

4. Public Health Department Aix‐Marseille University Marseille France

5. Patient Access and Community Engagement Swedish Orphan Biovitrum AB (Sobi™) Stockholm Sweden

6. Medical Affairs and Clinical Science Haemophilia Swedish Orphan Biovitrum AB (Sobi™) Stockholm Sweden

7. Faculty of Health and Education Manchester Metropolitan University Manchester UK

Funder

Swedish Orphan Biovitrum

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13901

Reference30 articles.

1. Hemophilia WFH.Annual Global Survey. 2020. Available at:https://www1.wfh.org/publications/files/pdf-2045.pdf(accessed 2 December 2022).

2. Social/economic costs and quality of life in patients with haemophilia in Europe

3. Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study

4. Factor VIII replacement is still the standard of care in haemophilia A;Aledort L;Blood Transfus,2019

5. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Point-of-care ultronography can help detect subclinical hemarthrosis in hemophilic patients undergoing regular optimal clotting factor prophylaxis to achieve zero bleeding;Expert Review of Hematology;2023-06-13